XENEXenon Pharmaceuticals Inc.

XENE Stock Price, Valuation & Chart | Xenon Pharmaceuticals Inc.

Compare

$60.770+1.04 (+1.74%)

At close · 21 Aug 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology XENE intrinsic value Is XENE overvalued or undervalued

Overview Financials Dividends Ratios

XENE Historical price chart

XENE Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization5.87B

PE Ratio-12.93

EPS-4.7

Trading Volume775.31K

Today's High/Low61.57/60.45

Dividend Yield0.00

52 Week High/Low72.66/35.6

Shares Outstanding96.67M

XENE Financial Statement

XENE Analyst ratings

XENE Analysis & performance metrics

XENE Company profile

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its…

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel…

XENE Management team

Name

Position

Ian C. Mortimer C.M.A., CPA, M.B.A.CEO

President, Chief Executive Officer & Director

Sherry Aulin C.A., CPACFO

Chief Financial Officer

Shelley McClCoskey B.A.

Executive Vice President of Human Resources

Christopher John Kenney M.D.

Chief Medical Officer

James R. Empfield Ph.D.

Executive Vice President of Drug Discovery

Matthew D. Ronsheim Ph.D.COO

Chief Operating Officer

Robin P. Sherrington Ph.D.

Executive Vice President of Strategy & Innovation

Andrea DiFabio J.D.

Chief Legal Officer & Corporate Secretary

Name

Position

Ian C. Mortimer C.M.A., CPA, M.B.A.CEO

President, Chief Executive Officer & Director

Sherry Aulin C.A., CPACFO

Chief Financial Officer

Shelley McClCoskey B.A.

Executive Vice President of Human Resources

Christopher John Kenney M.D.

Chief Medical Officer

James R. Empfield Ph.D.

Executive Vice President of Drug Discovery

Matthew D. Ronsheim Ph.D.COO

Chief Operating Officer

Robin P. Sherrington Ph.D.

Executive Vice President of Strategy & Innovation

Andrea DiFabio J.D.

Chief Legal Officer & Corporate Secretary

Management Team

Ian C. Mortimer C.M.A., CPA, M.B.A.CEO

President, Chief Executive Officer & Director

Sherry Aulin C.A., CPACFO

Chief Financial Officer

Shelley McClCoskey B.A.

Executive Vice President of Human Resources

Christopher John Kenney M.D.

Chief Medical Officer

James R. Empfield Ph.D.

Executive Vice President of Drug Discovery

Matthew D. Ronsheim Ph.D.COO

Chief Operating Officer

Robin P. Sherrington Ph.D.

Executive Vice President of Strategy & Innovation

Andrea DiFabio J.D.

Chief Legal Officer & Corporate Secretary

Management

Ian C. Mortimer C.M.A., CPA, M.B.A.CEO

President, Chief Executive Officer & Director

Sherry Aulin C.A., CPACFO

Chief Financial Officer

Shelley McClCoskey B.A.

Executive Vice President of Human Resources

Christopher John Kenney M.D.

Chief Medical Officer

James R. Empfield Ph.D.

Executive Vice President of Drug Discovery

Matthew D. Ronsheim Ph.D.COO

Chief Operating Officer

Robin P. Sherrington Ph.D.

Executive Vice President of Strategy & Innovation

Andrea DiFabio J.D.

Chief Legal Officer & Corporate Secretary

Total 8 executives

XENE Frequently asked questions

What is Xenon Pharmaceuticals Inc. (XENE) Stock Price?

Current stock price of Xenon Pharmaceuticals Inc. (XENE) stock is $60.770. The stock price is +1.74% higher in the session. The intraday range can be seen from this page. Volume of Xenon Pharmaceuticals Inc. (XENE) stock is 775.31K.

Last updated at 21 Aug 2026, 08:00 pm.

Why is the Xenon Pharmaceuticals Inc. (XENE) stock price going up or down today?

The stock price of Xenon Pharmaceuticals Inc. (XENE) can change with earnings, company news, and overall market sentiment. Xenon Pharmaceuticals Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Xenon Pharmaceuticals Inc. stock expensive at its current price?

Whether Xenon Pharmaceuticals Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for XENE on this page is -12.93. EPS on this page is -4.70. Compare those figures with peers and growth expectations before deciding if the current Xenon Pharmaceuticals Inc. price is justified.

How has the stock price of Xenon Pharmaceuticals Inc. (XENE) performed historically?

Historical performance for Xenon Pharmaceuticals Inc. (XENE) is shown on the price chart on this page. Review multi-period moves alongside volume to see how XENE reacted to past earnings and market events.

Should I buy Xenon Pharmaceuticals Inc. (XENE) stock, at this price?

Buying Xenon Pharmaceuticals Inc. (XENE) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.